Oncology Conference update

ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Prof. Valentina Guarneri

Prof. Valentina Guarneri
Prof. Matteo Lambertini

Prof. Matteo Lambertini
Prof. Federico Rojo

Prof. Federico Rojo
Publication Date

Mar 2024

download Downloadable resources

In this conference update video, Prof. Valentina Guarneri, Prof. Matteo Lambertini, and Prof. Federico Rojo summarise the key points presented at the highly anticipated EBCC-14 Industry Satellite Symposium and review the current and future treatment landscape for ER+/HER2- advanced breast cancer, with a focus on the metastatic luminal subtype.

 

Topics of discussion include:

  • Overview of the ESMO metastatic breast cancer living guidelines
  • Impact of endocrine resistance and sensitivity
  • The benefit of biomarker-selected endocrine-based therapies in ER+/HER2- advanced breast cancer
  • ESR1 mutation: clinical significance and testing strategies

 

Clinical Takeaways

  • Biomarker-selected endocrine therapies show greater PFS benefits in specific patient subgroups
  • Elacestrant, the first oral SERD to obtain FDA & EMA approval, demonstrates optimal efficacy in ESR1-mutated ER+/HER2- mBC following CDK4/6i treatment
  • Capivasertib, FDA-approved based on the CAPItello-291 study for AKT-pathway altered population, awaits EMA approval as of March 2024
  • ESR1 mutation, holding both prognostic and predictive value, warrants testing upon ET recurrence or progression, using tissue or liquid biopsy

Educational Objectives

  • Conduct a thorough evaluation to determine the underlying causes of HR-positive, HER2-negative breast cancer progression (with a focus on the metastatic luminal subtype)
  • Know the role and be able to implement genomic testing appropriately
  • Implement optimisation of treatment selection, and make the appropriate sequencing decisions in the context of shared decision making

"Valentina Guarneri, MD, PhD, is Full Professor of Oncology at the University of Padua, Head of the Division of Oncology 2 at the Istituto Oncologico Veneto, and head of the Specialization School in medical Oncology at the University of Padova. She completed her fellowship in Oncology in 2003, and she obtained her PhD Degree in Clinical and Experimental Oncology in 2007. In 2005 she was appointed Assistant Professor of Oncology at the University of Modena and Reggio Emilia, where she also chaired the Breast Unit. In 2005, she also completed a 6-month-research experience at the Department of Breast Medical Oncology, UT. MD Anderson Cancer Center, Houston, Texas, where in 2009 she was Visiting Assistant Professor. In 2014 she was appointed Associate Professor of Oncology at the University of Padua.  Prof Guarneri’s research interest is mainly focused on clinical and translational research for breast cancer patients. She has published more than 200 papers in peer-reviewed journals."

Prof. Valentina Guarneri has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory Role: Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Olema Oncology.

Speakers bureau: Amgen, Eli Lilly, GSK, Gilead, AstraZeneca, Novartis.

Expert testimony: Eli Lilly

Programme summary
Watch the video now
Share this programme
x-twitter
This educational programme is supported by an Independent Educational Grant from Menarini Stemline.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Menarini Stemline.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
BREAST CANCER CONNECT

BREAST CANCER CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Menarini Stemline Oncology, AstraZeneca and Thermo Fisher Scientific.

Meet the experts Independent IME approved

Other programmes of interest

animated-video Animated Video
Oncology 
Managing ADC toxicities in HER2+ metastatic breast cancer

Spotlight on nausea and vomiting

Experts
Dr Sara Tolaney
Endorsed by
ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Aug 2025
BREAST CANCER CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca.
Oncology 
The latest developments in BRAF-mutant and MSI-H mCRC

Expert insights on recent clinical and real-world data

Experts
Prof. Chiara Cremolini
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2025
GI CONNECT GI NURSES CONNECT PRECISION ONCOLOGY CONNECT
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
publication Scientific Publication
Oncology 
LEAP-012 publication

Expert insights on multimodal treatment for intermediate HCC

Experts
Prof. Arndt Vogel
Endorsed by
DiCE Global Liver Institute Blue Faery
ELPA
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this programme.
Oncology Hemato-oncology 
Innovating relapsed refractory multiple myeloma care

Unmet needs, therapy management, and real-world experience

Experts
Assoc. Prof. María Victoria Mateos, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Elena Zamagni
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
COR2ED
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
NTRK fusion testing and treatment in pediatric sarcoma

Make decisions for a young patient during his cancer journey

Experts
Dr Theodore Laetsch
Endorsed by
NTRKers
  • clock MIN
  • calendar Jun 2025
PRECISION ONCOLOGY CONNECT SARCOMA CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
micro-learning Micro learning - Video, slides and more

Module

4

of 4

module
Oncology 
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO)

Module 4: Treatment strategies for patients ineligible for IO or those with progression on IO 

Experts
Assoc. Prof. Lorenza Rimassa, Dr Amit Singal
Endorsed by
DiCE ELPA Global Liver Institute
Blue Faery AASLD
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2025
HCC CONNECT GI CONNECT Non-accredited Independent Medical Education
Educational programme supported by an Independent Educational Grant from Bayer.
Explore all programmes